HealthEquity, Inc. (NASDAQ:HQY) Receives Average Recommendation of “Moderate Buy” from Analysts

HealthEquity, Inc. (NASDAQ:HQY) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $107.23.

A number of brokerages recently issued reports on HQY. Bank of America boosted their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. Barrington Research restated an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. Deutsche Bank Aktiengesellschaft lifted their target price on HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Finally, The Goldman Sachs Group assumed coverage on HealthEquity in a research report on Friday. They set a “neutral” rating and a $108.00 price target on the stock.

HealthEquity Stock Performance

HQY stock opened at $98.98 on Friday. The company has a 50 day moving average price of $85.02 and a 200 day moving average price of $81.07. HealthEquity has a fifty-two week low of $62.10 and a fifty-two week high of $101.17. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The stock has a market capitalization of $8.64 billion, a PE ratio of 82.48, a price-to-earnings-growth ratio of 1.48 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. The company had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. Analysts forecast that HealthEquity will post 2.27 EPS for the current year.

Insider Buying and Selling

In other news, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total value of $99,847.90. Following the completion of the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now owns 54,719 shares in the company, valued at $4,540,582.62. This represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,536 shares of company stock valued at $884,517. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of HealthEquity by 1.7% during the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after purchasing an additional 149,133 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its position in HealthEquity by 1.8% during the 2nd quarter. Vaughan Nelson Investment Management L.P. now owns 616,860 shares of the company’s stock worth $53,173,000 after buying an additional 11,150 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in HealthEquity by 29.4% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock worth $5,535,000 after acquiring an additional 14,573 shares during the last quarter. Diversify Wealth Management LLC acquired a new position in HealthEquity in the 2nd quarter valued at approximately $8,182,000. Finally, Sequoia Financial Advisors LLC bought a new position in shares of HealthEquity during the second quarter valued at $1,122,000. 99.55% of the stock is currently owned by institutional investors and hedge funds.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.